A total of 11% of RSV patients experienced a cardiac event, abnormal heart rhythm, heart failure, or ischemic heart disease.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
A new study in The Lancet shows that the population prevalence of antibodies to SARS-CoV2, the virus that causes COVID-19, grew in Geneva, Switzerland, in April from 5% to 11%.
The newer antiviral was tied to a faster recovery than Tamiflu was.
The nearly 22% of US counties with higher proportions of black people accounted for 52% of COVID-19 cases and 58% of related deaths, according to a study published late last week in the Annals of Epidemiology.
The researchers accessed public data on Apr 13 to compare predictors of COVID-19 infections and deaths in counties with 13% or more black people and those with lower percentages.
A new analysis of data from a randomized clinical trial that found that mass distribution of the antibiotic azithromycin to children under 5 years old was associated with reduced childhood mortality in three African countries suggests mortality reduction may be linked to effects on pneumonia, diarrhea, or HIV/AIDS mortality.
Middle East respiratory syndrome (MERS) vaccines in England and Germany have demonstrated safety and immune response in phase 1 trials, becoming the second and third such vaccines to do so, according to studies yesterday in The Lancet Infectious Diseases.
An influenza research network established by the National Institutes of Health (NIH) in 2007 to help answer key questions during outbreaks now has a response plan to help it prepare for new challenges. A team led by the Centers for Infectious Disease Research and Development (CIDRAP), which publishes CIDRAP News, detailed the plan yesterday in Influenza and Other Respiratory Viruses.
Laboratory-confirmed influenza activity in the United States is now low, and influenza-like illness (ILI) activity is lower but still elevated, the Centers for Disease Control and Prevention (CDC) said today in its latest FluView report.
Each year, norovirus causes about 900 deaths, 110,000 hospitalizations, 2.3 million clinic visits, and 470,000 emergency department (ED) visits, at an annual healthcare cost of $430 million to $720 million, providing a substantial opportunity for a vaccine, according to a study in Clinical Infectious Diseases.
A paper yesterday in Current Opinion in Virology highlights a new effort led by the Center for Infectious Disease Research and Policy (CIDRAP) to track the development of universal influenza vaccine technologies.
Laboratory confirmed influenza continues to decrease sharply in the United States, and the number of people visiting clinics with influenza-like illness (ILI) fell last week, according to today's FluView report from the Centers for Disease Control and Prevention (CDC).
